Navigation Links
deCODE genetics Announces Third Quarter 2007 Financial Results
Date:11/5/2007

e have recently completed two studies confirming the lack of undesirable drug-drug interactions, as well as a pharmacology study of its effects in the presence and absence of aspirin. The results of that study provide further evidence that DG041 inhibits platelet activation and aggregation through a crucial pathway that is not targeted by existing medications. In order to manage risk and expand our therapeutic pipeline, we are actively investigating partnership opportunities for these and earlier stage programs. Our financial results this year demonstrate our ability to create valuable assets through product development while leveraging our capabilities to generate near-term revenue streams," Dr. Stefansson concluded.

Recent highlights include:

Product Development

-- Heart attack. In its drug development program targeting the leukotriene

pathway for the prevention of heart attack, deCODE last month began

enrolling patients for its Phase IIa clinical trial for DG051, the

company's leukotriene A4 hydrolase inhibitor. In Phase I studies

completed earlier this year, DG051 significantly reduced the production

of leukotriene B4 (LTB4) in a dose dependent manner. LTB4 is a pro-

inflammatory molecule that deCODE's gene discovery and functional

biology work identified as a key factor in modulating risk of heart

attack. The Phase I studies showed DG051 to be safe and well-tolerated

at all dose levels tested, with a favourable pharmacokinetic profile.

DG051 was also recently evaluated in a 28-day Phase I study that

further demonstrated that the drug can deliver significant, sustained

reductions in LTB4 levels with once-daily dosing. The Phase IIa is a

randomized, double-blind, placebo-controlled trial that will examine

the impact of DG051 on the production of LTB4 as well as the compound's

pharmacokinetic and safety and tole
'/>"/>

SOURCE deCODE genetics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
4. Response Genetics Reports Second Quarter 2007 Financial Results
5. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
(Date:10/22/2014)... Md. , Oct. 22, 2014   Synthetic ... developing novel pathogen-specific therapies for serious infections and diseases, ... has issued a Notice of Allowance for a composition ... its C. difficile program, SYN-004. This is ... SYN-004 in the U.S. and adds to the Company,s ...
(Date:10/20/2014)... 2014 The report “Pharmacy Automation ... Packaging and Labeling Systems, Table-top Counters) by End-user ... Forecasts & Trends to 2019” analyzes and studies ... North America, Europe, Asia-Pacific, and the Rest of ... and 30 figures spread through 300 pages and ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Oct. 16 Compendia Bioscience, Inc.,today announced ... Premium Edition, a high-value product extension of ... Oncomine Research,Premium Edition includes custom gene filters, ... support for Oncomine Concepts Map,including the ability ...
... DRRX ) announced today that it will be hosting ... at 12:00 p.m. Eastern Time. A live audio,webcast of ... and will,be available by accessing DURECT,s homepage at ... to participate during the,live webcast, the call will be ...
... will receive milestones and ... by Altair - Altair to conduct clinical development ... FRANCISCO, Oct. 16 ,Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... Inc., a new venture,capital-funded biotechnology company, has been created to ...
Cached Biology Technology:Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 3Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 4Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 5
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
(Date:10/14/2014)... Research shows SIRT6—a protein known to inhibit the ... of skin cancers by turning on an enzyme that ... , Previously considered protective, SIRT6 is part of a ... genomic stability and prevent some of the genetic flaws ... can lead to cancer. This study, in the journal,s ...
(Date:10/14/2014)... leading questions is how to produce enough food to ... Food and Agriculture Organization of the United Nations predicts ... 40 years to feed a growing global population, and ... in food production. Plants—grains, cereals, fruits, vegetables, and ... Current research must tap into our knowledge of how ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... members gather at a picnic in your backyard, there may be ... When flies visit your party, be glad they don,t bring ... those are just the ones we know about. An Iowa ... have recently researched the fly family tree -- one of the ...
... dead sea bottoms to life. This creates the necessary ... nature itself to deal with eutrophication. By conducting pilot ... University of Gothenburg have demonstrated that pumping oxygen-rich surface ... wind-driven pump is now to be tested in open ...
... Harris, professor in the University of Minnesota,s College of Biological ... the National Institutes of Health to direct a large-scale research ... treating HIV and other viral diseases. The goal of ... the protein (APOBEC3G) to better understand how it interacts with ...
Cached Biology News:Too many relatives ruining your picnic? Be glad the flies don't invite their cousins 2Oxygenation at a depth of 120 meters can save the Baltic Sea 2U of M scientist gets 5-year, $10 million grant to direct innovative HIV research program 2
... a fluorescence scanner with 1 or 2 ... Protein, CGH, ) spotted on standard slides ... InnoScan700 scanners include three different models:, ... simultaneous dual fluorescence scanner (635nm and 532nm). ...
... Non-Radioactive Translation Detection Systems allow non-radioactive ... Using these systems, biotinylated lysine residues ... translation, eliminating the need for labeling ... acids. This biotinylated lysine is added ...
... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
Biology Products: